Key Highlights

  • Nautilus Biotechnology (NASDAQ:NAUT) rose 206.00% over one month in published market data as of October 28, 2026, including 22.40% in the latest week, with a three-month gain of 194.23%.
  • The company reported third quarter results on October 27, 2026: a net loss of USD 15.6 million, revenue of USD 230,000 and cash and investments of USD 114.3 million.
  • Management said cash lasts into the first quarter of 2028 and that it is exploring fundraising before mid-2027, so Nautilus Biotechnology (NASDAQ:NAUT) holders face possible dilution.
  • Roth Capital initiated coverage on October 19, 2026 with a Buy rating and a USD 3.50 target, as reported, about 14% above the latest quoted USD 3.06.

What Moved the Stock

Nautilus Biotechnology (NASDAQ:NAUT) is a Seattle proteomics company developing Voyager, a benchtop instrument designed to measure up to 10 billion intact proteins in one run. The one-month gain follows a series of events rather than one release: the Roth Capital initiation on October 19, 2026 and third quarter results on October 27, 2026. The company announced no deal, financing or clinical result in that window that explains a 206.00% gain, and shares were reported near USD 1 at the end of September, so a low base magnified the move. Year to date the stock is up 57.73%, which shows how much of the gain came in the past month.

Voyager Timeline and Cash

On the October 27, 2026 call, management said a beta Voyager unit should be placed by the end of 2026, with commercial launch and pre-orders planned for early 2027 and instrument shipments in mid-2027. Baylor College of Medicine is among the first Early Access customers, and an AKT1 assay is expected to enter Early Access in late 2026. Quarterly revenue of USD 230,000 beat a USD 206,250 consensus, and the loss of USD 0.12 per share was narrower than the USD 0.14 expected. Operating expenses were USD 16.9 million, of which USD 10.2 million was research and development. The tau proteoform work behind the first assay was published in Nature Methods, and management expects fourth quarter revenue to grow sequentially and full-year 2026 revenue to exceed its earlier outlook of about USD 0.5 million.

Risks and Next Steps

The company has almost no product revenue, so the valuation rests on a launch that is still a year away. Cash fell from USD 129.2 million to USD 114.3 million in one quarter, a use of about USD 14.9 million, and an equity raise would add shares to the count. The Roth target of USD 3.50 is about 14% above USD 3.06, simple arithmetic on two published numbers, which leaves limited room if the rally continues. After a 206.00% month, sharp reversals are possible. Nautilus Biotechnology (NASDAQ:NAUT) investors should watch the beta placement, the AKT1 Early Access start and any financing announcement. Chief Executive Sujal Patel describes the mission as making functional biology measurable, but the company still has to show that customers will pay for the data. Full-year operating expense growth is guided to the single digits.

Where Things Stand

Nautilus Biotechnology (NASDAQ:NAUT) gained 206.00% because a pre-commercial platform company received an analyst initiation and a better-than-expected third quarter report while shares started from a low base, and no single announcement explains it fully. The case for a lasting re-rating is thin, since revenue is USD 230,000 a quarter and launch is dated early 2027. The next tests are the beta placement by the end of 2026, the AKT1 Early Access start and any financing before mid-2027.